TikTok's epithalon dosing advice is dangerously vague

What did @simplymyglp1journ actually say?

The creator isn't making strong claims here. She's asking a genuine question: what protocol works for Epithalon? She mentions seeing dosage ranges from 100 mcg per day all the way to 5-10 mg for 10-30 day cycles, and she's openly confused about which approach makes sense. "I would hate to waste it," she says, which is fair. This is a crowdsourced dosing conversation, not medical advice. That's worth acknowledging upfront.

To her credit, she's not prescribing anything or claiming Epithalon will fix a specific condition. She's asking what protocols exist. The problem is that TikTok comment sections are not clinical trials, and the range she's describing, from microdose territory to full peptide cycles, reflects genuine uncertainty in the research, not just social media noise. The confusion is real. The solution isn't a comment thread.

Does the science back this up?

Here's the honest answer: Epithalon (also spelled Epitalon or Epithalamin) has more animal and in-vitro research behind it than most peptides discussed on TikTok, but human clinical data is thin. The dosing confusion she's describing is legitimate because no standardized human dosing protocol has been established in peer-reviewed literature.

Epithalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, derived from epithalamin, a polypeptide extract from the pineal gland. The bulk of foundational research comes from Vladimir Khavinson's group in Russia, published across several decades. Khavinson et al. (2002, Bulletin of Experimental Biology and Medicine) reported telomerase activation in human somatic cells, which generated significant longevity interest. Separate work by Anisimov et al. (2003, Mechanisms of Ageing and Development) showed life extension in mice at doses that do not translate directly to human equivalents. The 10-day injection cycle seen in some protocols appears to derive loosely from this Soviet-era clinical use of epithalamin, not Epithalon specifically, and not from randomized controlled trials in healthy adults.

The 100 mcg microdose range has essentially no published clinical backing. The 5-10 mg range referenced in the video aligns more closely with the older Russian clinical studies, but those involved intramuscular administration of a different compound. Extrapolating those numbers to subcutaneous Epithalon injections in 2024 is a stretch.

What did they get wrong (or right)?

She got the confusion right. The dosing landscape for Epithalon is genuinely inconsistent across sources, and acknowledging that openly is more honest than many peptide influencers who state protocols as if they've been validated. She deserves credit for that.

What she got wrong, or at least incomplete, is framing this as a solvable question that TikTok comments can answer. The real issue isn't that the community hasn't landed on the right dose. It's that no rigorous human pharmacokinetic study has established what dose does what, at what frequency, in which populations. The "twice a year thing" framing also implies a maintenance cycle logic that sounds clinical but isn't supported by human trial data. That framing can create false confidence in a protocol that has no validated structure.

She also doesn't mention that sourcing, purity, and sterility of research peptides vary enormously, which affects both safety and any conclusions drawn about whether a protocol "worked." Dose discussions without purity discussions are incomplete at best.

What should you actually know?

If you're curious about Epithalon, here's what the actual research gives you, and what it doesn't. Khavinson's group published repeated observations of telomerase activation and antioxidant effects in cellular and animal models. Those findings are real and worth tracking. What they don't give you is a validated subcutaneous dosing protocol for humans, because that work hasn't been done in a controlled, peer-reviewed format accessible outside of Soviet-era institutional medicine.

The 10-day and 20-day cycle conventions circulating online appear to originate from clinical use of epithalamin injections in geriatric and oncology settings in Russia, documented in Khavinson and Morozov (2003, Neuroendocrinology Letters). Those weren't recreational optimization protocols. They were supervised medical interventions in patient populations. That context matters.

• No FDA-approved human dosing exists for Epithalon.
• Sourcing and peptide purity are variables that dosing discussions almost never account for.
• The animal longevity data is interesting but does not establish a human dose-response relationship.
• Telehealth platforms operating under regulatory oversight do not offer unsupervised peptide protocols for good reason.
• If you're considering any peptide therapy, that conversation belongs with a licensed clinician who can review your bloodwork, not a comment section.